Industry News
Pharmaceutical Industry News
The company is winding down the…
The company is winding down the sale of a handful of its insulin products across different European countries, according to the European Medicines Agency.
Karyopharm has provided mixed…
Karyopharm has provided mixed results from a phase 3 trial testing Xpovio in combination with Incyte and Novartis’ blockbuster Jakafi in patients with first-line myelofibrosis. The company will discuss the results with the FDA in
Despite policy uncertainties in…
Despite policy uncertainties in recent years, WuXi Biologics’ emphasis on its U.S. operations continued to pay off in 2025, with the States accounting for a major portion of the record number of projects the CRDMO
Gilead has partnered with digital…
Gilead has partnered with digital health company Manta Cares to get tools for navigating lung and breast cancer care pathways to patients.
Wilmington PharmaTech, a CDMO…
Wilmington PharmaTech, a CDMO specializing in churning out complex custom APIs for small molecules, will drop $50 million in a move to double the current production capacity at its Delaware facility.
India’s Strides Pharma issued a…
India’s Strides Pharma issued a voluntary recall for 89,592 bottles of liquid ibuprofen pain medication for children following reports of contamination.
The Supreme Court denied Takeda…
The Supreme Court denied Takeda and Lilly's bid to stop the case from moving forward. If the drugmakers come up short in defending against the RICO allegations, the companies could be on the line for
AbbVie is swinging for the fences…
AbbVie is swinging for the fences with a new partnership in support of cancer awareness and research.
Gilead increased CEO Daniel…
Gilead increased CEO Daniel O’Day's compensation by 20% in 2025, to $28.4 million, putting him among a group of the highest-paid chief executives in the industry. It was the largest raise for O’Day, 61, in
Insmed has revealed results from a…
Insmed has revealed results from a trial of Arikayce, which could pave the way for a significant label expansion for the Mycobacterium avium complex (MAC) treatment.
A pair of rivals developing drugs…
A pair of rivals developing drugs for common retinal diseases are not seeing eye to eye. EyePoint on Friday filed a lawsuit in Massachusetts Superior Court accusing Ocular Therapeutix of engaging in a “malicious campaign”
The agency identified 14 cases of…
The agency identified 14 cases of vitamin B6 deficiency-associated seizures in patients using the common Parkinson's disease drug combo of levodopa and carbidopa.
Watch out, Johnson & Johnson….
Watch out, Johnson & Johnson. Dizal has reported positive phase 3 results for its oral Zegfrovy that could put more pressure on the pharma giant’s injectable Rybrevant in non-small cell lung cancer.
Novartis is investing more than…
Novartis is investing more than 3.3 billion Chinese yuan (roughly $480 million) to soup up its manufacturing facility in Beijing and strengthen its R&D campus in Shanghai, where the company’s China headquarters are also located.
The FDA has scheduled a public…
The FDA has scheduled a public hearing for June 12 to hear input on the Commissioner’s National Priority Voucher program, which it introduced last June. So far, the program has resulted in four ultraspeedy drug
Seventeen large pharmaceutical…
Seventeen large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more than 22,000 employees last year.
With patents expiring today in…
With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions in the country, with
Not long after lending its support…
Not long after lending its support to a documentary aimed at shining a light on the often-overlooked stories of women with hemophilia, Sanofi is continuing its film-focused collaboration with patient engagement agency Believe Limited.
The status of the CDC’s vaccine…
The status of the CDC’s vaccine advisory panel was thrown into further disarray this week after an outspoken member of the ACIP—whose appointment was invalidated by a federal judge Monday—declared that the group was being
The new FDA nod makes Rhythm…
The new FDA nod makes Rhythm Pharma's Imcivree the first approved drug for acquired hypothalamic obesity and brings the drug's first expansion beyond rare genetic-driven obesities.